Exelixis, Inc. (EXEL) Director George A. Scangos Sells 25,000 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 25,000 shares of the company’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $16.85, for a total value of $421,250.00. Following the transaction, the director now directly owns 1,561,981 shares in the company, valued at approximately $26,319,379.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ:EXEL traded up $0.29 during mid-day trading on Thursday, hitting $17.49. The company had a trading volume of 21,406 shares, compared to its average volume of 3,549,085. Exelixis, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $32.50. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 34.12 and a beta of 1.96.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.12. Exelixis had a return on equity of 65.68% and a net margin of 48.17%. The firm had revenue of $186.10 million for the quarter, compared to analyst estimates of $157.37 million. During the same quarter in the prior year, the firm posted $0.06 earnings per share. The company’s quarterly revenue was up 88.0% on a year-over-year basis. sell-side analysts expect that Exelixis, Inc. will post 1.03 EPS for the current year.

Several equities analysts have recently issued reports on the company. ValuEngine lowered Exelixis from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 4th. Stifel Nicolaus cut their price target on Exelixis from $29.00 to $25.00 and set a “hold” rating on the stock in a research note on Wednesday, August 1st. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price target on the stock in a research note on Tuesday, July 31st. BidaskClub lowered Exelixis from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 11th. Finally, Cann reaffirmed a “buy” rating and set a $40.00 price target on shares of Exelixis in a research note on Wednesday, May 30th. Three analysts have rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $30.70.

A number of large investors have recently added to or reduced their stakes in the business. James Investment Research Inc. acquired a new stake in shares of Exelixis during the second quarter worth about $133,000. TLP Group LLC acquired a new stake in shares of Exelixis during the first quarter worth about $179,000. Washington Trust Bank acquired a new stake in shares of Exelixis during the second quarter worth about $213,000. Advisors Asset Management Inc. raised its position in shares of Exelixis by 94.7% during the second quarter. Advisors Asset Management Inc. now owns 41,168 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 20,025 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Exelixis during the second quarter worth about $217,000. 80.90% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Article: How to use beta for portfolio diversification

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply